Aguettant, an Independent French Pharmaceutical Company, and PX’Therapeutics, a French Contract Manufacturing Organization Dedicated to the Development of Recombinant Proteins, Join Forces to Boost Their Activities

LYON & GRENOBLE, France--(BUSINESS WIRE)--Aguettant, a pioneer in drugs for injection since 1903, invests in the field of biotechnologies. Aguettant Biotech, a fully-owned subsidiary of Aguettant Santé, acquires a majority stake in the equity of PX’Therapeutics.